治疗注意缺陷多动障碍的长效缓释药物——MYDAYIS

Long-acting drug for the treatment of attention deficit hyperactivity disorder——MYDAYIS

MYDAYIS是由Shire公司研制的由单一实体苯丙胺混合盐组成的中枢神经系统兴奋剂,2017年6月,FDA批准其用于治疗13岁及以上患者的注意缺陷多动障碍。MYDAYIS采用的创新长效缓释剂型包含有3种类型的药物释放珠粒,可持续释放有效成分,药效可维持16 h,每日只需口服1次,为患者提供了极大的便利。经5项临床试验证实了其临床疗效。本文就MYDAYIS的基本信息、作用机制、药动学、临床试验及应用等研发动态作一概述,以期为临床用药起到指导作用。

MYDAYIS is a central nervous system stimulant composed of a single entity amphetamine mixed salt developed by Shire Corporation, which has been approved by FDA for the treatment of attention deficit hyperactivity disorder in patients aged at 13 years old and older in June 2017. This innovative long-acting sustained-release drug contains three kinds of drug release pellets, which can be sustainably released, and the effect of this drug can sustain for 16 hours in the case of only once a day. MYDAYIS provides great convenience for patients, and the evaluation results of 5 clinical studies confirmed the significant efficacy of this drug. In this paper, the basic information, mechanism of action, pharmacokinetics, clinical trials and applications of MYDAYIS are summarized in order to guide the clinical use of this drug.